MK-677 (Ibutamoren)

Verdict

What Is MK-677?

MK-677 is an oral, non-peptide ghrelin receptor agonist developed by Merck Research Laboratories in the 1990s. Its generic name is ibutamoren mesylate.

It is not a SARM, not a peptide, and not exogenous growth hormone. It belongs to a class of compounds called growth hormone secretagogues -- agents that stimulate the body's own production of growth hormone rather than replacing it from an outside source.^[7]

That distinction matters. Exogenous GH (injectable HGH) delivers growth hormone directly and shuts down endogenous production via negative feedback. MK-677 does the opposite: it prods the pituitary gland to release more of its own GH while preserving the natural pulsatile rhythm that the body uses to regulate tissue growth and repair.

Despite more than two decades of clinical trials, MK-677 has never received FDA approval for any indication. Multiple Phase II trials were completed. No Phase III trial was ever initiated. The compound is currently sold as a "research chemical" and is not a controlled substance in most jurisdictions.

The fact that Merck invested decades of clinical research into this compound and ultimately abandoned it is a signal worth paying attention to.

The GH/IGF-1 elevation was never in doubt. What the clinical trials consistently failed to demonstrate was that elevating those markers translated to the outcomes that mattered -- strength, functional capacity, and body composition improvement at a meaningful scale.

Mechanism of Action

The human body produces growth hormone in pulses, primarily during deep sleep. These pulses are regulated by a push-pull system: GHRH (growth hormone-releasing hormone) tells the pituitary to release GH, while somatostatin acts as the brake and tells it to stop.

MK-677 enters this system through a third door -- the ghrelin receptor.^[8]

The Technical Layer

For those who want the deeper mechanism: GHS-R1a is a G-protein coupled receptor -- a type of cell-surface switch that triggers internal signaling chains. When MK-677 activates it, calcium levels rise inside the pituitary's GH-producing cells (somatotrophs), which causes them to release stored growth hormone.^[7]

This pathway is separate from the GHRH receptor, which matters for two reasons. First, MK-677 works alongside the body's own GHRH signals rather than competing with them -- the two pathways amplify each other. Second, MK-677 can partially override somatostatin, the hormone that normally puts the brakes on GH release. GHRH alone cannot do this.^[7]

One more detail worth noting: the ghrelin receptor has roughly 50% baseline activity even when nothing is bound to it -- it is always partially "on."^[7] MK-677 pushes an already-active receptor into higher gear.

graph TD
 A["MK-677
Oral Administration"] --> B["GHS-R1a
Ghrelin Receptor"]

 B --> C["Pituitary
Somatotrophs"]
 C --> D["Growth Hormone
Pulsatile Release"]
 D --> E["Liver
GH-R Activation"]
 E --> F["IGF-1
Production"]

 F --> G["Muscle
Protein Synthesis Signal"]
 F --> H["Bone
Osteoblast Stimulation"]
 F --> I["Brain
Neuroprotective Signals"]

 B --> J["Hypothalamus
NPY/AgRP Neurons"]
 J --> K["Appetite
INCREASE"]

 B --> L["Peripheral Tissues
Insulin Signaling"]
 L --> M["Insulin Sensitivity
DECREASE"]

 style A fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style B fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style C fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style D fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style E fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style F fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style G fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style H fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style I fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style J fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style K fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style L fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style M fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 

Clinical Research: Peer-Reviewed Evidence

MK-677 has more clinical trial data than most compounds in the research chemical space. That is the good news.

The bad news is that the data tells a story the internet largely ignores.

GH and IGF-1 Elevation: The Part That Works

This is the undisputed finding. MK-677 raises growth hormone and IGF-1. It does so reliably, dose-dependently, and sustainably over at least 12 months of continuous administration.

Chapman et al. (1996) demonstrated that daily oral MK-677 restored IGF-1 levels to the range of young adults in elderly subjects within 2-4 weeks. Mean 24-hour GH levels increased significantly, and the GH pulse during deep sleep was particularly amplified.^[3]

The dose-response curve is clear: 2 mg produced minimal effect, 10 mg produced partial IGF-1 elevation, and 25 mg achieved near-maximal effect. Across studies, the IGF-1 increase ranged from 40-60% above baseline depending on the population tested.^[3]

Nass et al. (2008) confirmed that this IGF-1 elevation was maintained for at least 12 months of continuous use.^[2]

Body Composition: The Critical Gap

This is where MK-677's narrative falls apart.

The short-term signal (Murphy et al., 1998): In a 7-day study, 25 mg/day reversed nitrogen wasting -- meaning the body stopped breaking down protein for energy -- in calorie-restricted healthy volunteers. This is a genuine anti-catabolic signal.^[1]

But 7 days is not a body composition study. It is a metabolic snapshot.

The long-term reality (Nass et al., 2008): This is the gold standard MK-677 study -- a 2-year, randomized, placebo-controlled trial in healthy adults over age 65. The results are the single most important data point for anyone considering MK-677 for physique purposes:^[2]

• Fat-free mass increased ~1.5 kg in year 1. Sounds promising -- until the caveats emerge.
• Year 2: gains did not persist. The fat-free mass increase plateaued and did not continue despite maintained IGF-1 elevation.
• Zero improvement in strength. No change in grip strength. No change in functional capacity tests.
• Fat mass was not reduced. MK-677 did not improve body fat levels.
• Fasting glucose increased significantly. The metabolic trade-off was real and measurable.

The ~1.5 kg fat-free mass gain in year one likely includes water and glycogen in addition to actual lean tissue. For context, creatine loading achieves 1-2 kg of fat-free mass increase within weeks -- much of which is also intracellular water.

The comparison is not flattering for a compound that carries meaningful metabolic risk.

The hip fracture data (Bach et al., 2004): MK-677 was tested in hip fracture patients to see if GH elevation would improve recovery. It did not. Despite raising IGF-1, there was no improvement in functional recovery outcomes.^[11]

Sleep Architecture: The Strongest Finding

If there is one area where MK-677 earns its reputation, it is sleep.

Copinschi et al. (1997) conducted a polysomnography study -- the gold standard for measuring sleep -- in young healthy adults taking MK-677. The findings were striking:^[4]

• Stage IV (deep/slow-wave) sleep increased by approximately 50%.
• REM sleep increased by approximately 20%.
• These were objective polysomnography measurements, not self-reported sleep quality questionnaires.

The mechanism is straightforward: growth hormone secretion is naturally highest during deep sleep. Ghrelin receptor activation in the hypothalamus promotes sleep-consolidating signals that extend the duration of these GH-rich sleep phases.

The result is more time in the most restorative stages of sleep -- the phases where tissue repair, immune function, and memory consolidation are most active.

This is the most consistently positive and clinically relevant finding across all MK-677 research. For those interested in broader sleep optimization, the sleep and recovery protocol covers complementary strategies including magnesium and L-theanine.

Bone Metabolism

Increased markers of bone turnover -- signs that bone is being actively remodeled -- have been observed with MK-677 administration.^[5],[6] The GH/IGF-1 axis is a known driver of osteoblast (bone-building cell) activity, so this finding is mechanistically expected.

However, no RCT has demonstrated actual fracture reduction or significant bone mineral density increase with MK-677. The data consists of surrogate markers (bone turnover indicators), not clinical endpoints (fewer fractures, denser bones).

This remains theoretical potential, not proven benefit. For bone health context, see vitamin D3 + K2.

The Alzheimer's Trial: An Honest Negative

Sevigny et al. (2008) tested MK-677 as a potential Alzheimer's disease treatment. The rationale was sound on paper: IGF-1 has neuroprotective properties in animal models, and MK-677 reliably raises IGF-1.^[13]

The trial failed its primary endpoint. No cognitive improvement was observed despite successful IGF-1 elevation.

This finding matters for intellectual honesty. If IGF-1 elevation alone were sufficient to protect brain function in humans, this trial should have shown at least a signal. It showed nothing. The preclinical promise did not translate.

Common Questions: Dosing, Safety, Comparisons

Dosing in Clinical Literature

Most clinical trials administered 25 mg/day orally, taken once daily.^[1],[2],[3] The dose-response data from Chapman et al. confirmed that 10 mg produced partial IGF-1 elevation while 25 mg achieved near-maximal effect.

No clinical data exists above 25 mg. The approximately 24-hour half-life supports once-daily administration.^[3]

Enhancement community observations report administration ranges of 10-25 mg, often taken before bed to leverage the sleep-enhancing effect and reduce the impact of daytime appetite stimulation. These observations are consistent with the clinical dosing literature but are not controlled data.

MK-677 vs. Exogenous GH (HGH)

The comparison highlights a central trade-off. MK-677 is oral, preserves pulsatile GH release, and does not suppress endogenous production. Exogenous GH produces higher IGF-1 levels, does not increase appetite, and has a milder insulin impact relative to its GH-elevating potency.

Neither compound has strong clinical evidence for muscle building in the absence of concurrent anabolic compounds.

MK-677 vs. GHRP Peptides

Injectable GH secretagogues -- Ipamorelin, GHRP-2, GHRP-6, Hexarelin -- cause acute GH pulses of shorter duration. MK-677's 24-hour half-life provides sustained elevation rather than isolated spikes.

Key differences worth noting: GHRP-6 also stimulates appetite through ghrelin-like mechanisms, while Ipamorelin does not. Injectable peptides may allow more precise timing of GH pulses around training windows.

MK-677's oral route is its primary practical advantage -- no injections, no reconstitution, no refrigeration.

graph LR
 subgraph PATH_A["MK-677 — ORAL"]
 A1["Oral Tablet"] --> A2["Ghrelin-R
Agonism"]
 A2 --> A3["Pulsatile GH"]
 A3 --> A4["Moderate
IGF-1 Rise"]
 end

 subgraph PATH_B["EXOGENOUS GH — INJECTION"]
 B1["SC Injection"] --> B2["Direct GH
Elevation"]
 B2 --> B3["Flat-Line GH"]
 B3 --> B4["Higher
IGF-1 Rise"]
 end

 subgraph PATH_C["GHRP PEPTIDES — INJECTION"]
 C1["SC Injection"] --> C2["Various GHS-R
GHRH-R"]
 C2 --> C3["Acute GH
Pulse"]
 C3 --> C4["Short-Duration
IGF-1 Rise"]
 end

 style PATH_A fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style PATH_B fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style PATH_C fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style A1 fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style A2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style A3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style A4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style B1 fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style B2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style B3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style B4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style C1 fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style C2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style C3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style C4 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 

Risk Profile Analysis

Insulin Resistance (Primary Concern)

This is the most important safety concern and the primary reason MK-677 never reached the market.

The Nass et al. two-year trial documented statistically significant fasting glucose elevation in the MK-677 group -- an average increase of 0.3 mmol/L. Some individual subjects crossed into the pre-diabetic range. This occurred under controlled conditions with medical monitoring in otherwise healthy elderly adults.^[2]

The mechanism is not mysterious. Gauna et al. (2004) demonstrated that activating the ghrelin receptor -- precisely what MK-677 does -- directly impairs how the body responds to insulin.^[9]

Vestergaard et al. (2008) confirmed this from a different angle: ghrelin infusion increased blood glucose and decreased insulin sensitivity within hours.^[10]

Internet Myth: "The insulin resistance is manageable and not a real concern"

The Nass 2008 trial showed significant fasting glucose elevation under controlled conditions with medical supervision. In enhancement populations -- with higher caloric intake, potential concurrent compound use, and no medical monitoring -- the metabolic risk is amplified, not diminished.

Merck could not overcome this barrier in 20+ years of clinical development. That fact alone should calibrate expectations about how "manageable" this side effect truly is.

For those researching insulin sensitivity support, berberine has well-characterized AMPK-activating properties, and omega-3 fatty acids and taurine have data supporting metabolic health.

Appetite Increase

Appetite increase is a direct consequence of ghrelin receptor activation, reported consistently across every clinical trial and in virtually every enhancement community account. This is not mild appetite stimulation. It can be persistent and pronounced.

For individuals in a caloric deficit, this creates a paradox: MK-677 may help preserve muscle protein, but the intense hunger may undermine the ability to maintain the deficit in the first place.

Enhancement community observations suggest evening administration may reduce the impact on daytime eating patterns, though the appetite effect is not eliminated.

Water Retention and Edema

GH and IGF-1 elevation promotes sodium and water retention through the kidneys. Peripheral edema -- swelling in the hands, feet, and face -- was reported in clinical trials.^[12] The enhancement community consistently reports facial puffiness, hand swelling, and scale weight increases that do not reflect actual lean tissue gains.

This matters practically. Scale weight changes on MK-677 cannot be reliably interpreted as muscle gain. Water retention will mask physique assessment and confound body composition tracking.

The effect is dose-dependent and resolves upon discontinuation. For another compound where water retention confounds scale interpretation, see creatine.

Joint Pain and Carpal Tunnel-Like Symptoms

Numbness and tingling in the hands, consistent with carpal tunnel syndrome, has been reported. This mirrors the side effect profile of exogenous GH administration -- elevated GH/IGF-1 levels promote fluid accumulation in connective tissue, which can compress the nerves that run through tight anatomical spaces.

More common at the higher end of the dosing range and with prolonged use.

Prolactin Elevation

Small, transient increases in prolactin (a hormone involved in lactation and immune regulation) have been observed in some studies. Generally not clinically significant at 25 mg/day.

Worth monitoring for individuals already managing prolactin levels -- particularly those using 19-nor compounds (nandrolone, trenbolone) where prolactin elevation is already a known concern.

Theoretical Long-Term IGF-1 Concerns

Chronically elevated IGF-1 is associated with increased cancer risk in epidemiological data. This is not specific to MK-677 -- it applies to any strategy that maintains elevated IGF-1 over extended periods, including exogenous GH use.

The two-year Nass trial did not report cancer events, but the sample was small and the duration insufficient for cancer surveillance. This remains a theoretical concern, not a documented MK-677-specific finding.

graph LR
 subgraph WK1["WEEKS 1-4"]
 W1A["IGF-1 Rising"]
 W1B["Appetite Onset"]
 W1C["Sleep Improvement"]
 W1D["Glucose Rising"]
 end

 subgraph MO1["MONTHS 1-6"]
 M1A["IGF-1 Near Peak"]
 M1B["FFM +~1 kg"]
 M1C["Water Retention
Stabilized"]
 M1D["Insulin Resistance
Measurable"]
 end

 subgraph MO6["MONTHS 6-12"]
 M6A["FFM Plateau
~1.5 kg max"]
 M6B["Sleep Benefit
Sustained"]
 M6C["Insulin Resistance
Persistent"]
 M6D["Glucose Elevated"]
 end

 subgraph MO12["MONTHS 12-24"]
 M12A["FFM Gains STOP"]
 M12B["Insulin Resistance
STILL Present"]
 M12C["Sleep Benefit
Still Active"]
 M12D["Returns Diminish
Risk Remains"]
 end

 WK1 --> MO1
 MO1 --> MO6
 MO6 --> MO12

 style WK1 fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style MO1 fill:#f4f4f5,stroke:#5e5645,stroke-width:2px,color:#0a0a0a
 style MO6 fill:#f4f4f5,stroke:#8a7d68,stroke-width:2px,color:#0a0a0a
 style MO12 fill:#e4e4e7,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style W1A fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style W1B fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style W1C fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style W1D fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M1A fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M1B fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M1C fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M1D fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M6A fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M6B fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M6C fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M6D fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M12A fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style M12B fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 style M12C fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M12D fill:#e4e4e7,stroke:#2a2236,stroke-width:2px,color:#0a0a0a
 

Evidence Synthesis

graph TD
 subgraph STRONG["STRONG EVIDENCE — Tier 1 Multiple RCTs"]
 S1["Raises GH and IGF-1"]
 S2["Improves Deep Sleep +50%"]
 S3["Increases Appetite"]
 S4["Impairs Insulin Sensitivity"]
 S5["Does NOT Improve
Strength or Function"]
 end

 subgraph MODERATE["MODERATE EVIDENCE — Tier 1-2 Limited Data"]
 M1["Anti-Catabolic in
Caloric Deficit 7 days"]
 M2["Increases Bone
Turnover Markers"]
 M3["Causes Water
Retention and Edema"]
 end

 subgraph WEAK["WEAK OR NO EVIDENCE — Tier 2-3"]
 W1["Builds Significant
Muscle Mass"]
 W2["Improves Strength"]
 W3["Provides Cognitive
Enhancement"]
 W4["Long-Term Body
Composition Benefit"]
 end

 style STRONG fill:#f4f4f5,stroke:#2a2236,stroke-width:3px,color:#0a0a0a
 style MODERATE fill:#f4f4f5,stroke:#8a7d68,stroke-width:2px,color:#0a0a0a
 style WEAK fill:#e4e4e7,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style S1 fill:#f4f4f5,stroke:#5e5645,stroke-width:1px,color:#0a0a0a
 style S2 fill:#f4f4f5,stroke:#5e5645,stroke-width:1px,color:#0a0a0a
 style S3 fill:#f4f4f5,stroke:#5e5645,stroke-width:1px,color:#0a0a0a
 style S4 fill:#f4f4f5,stroke:#5e5645,stroke-width:1px,color:#0a0a0a
 style S5 fill:#f4f4f5,stroke:#5e5645,stroke-width:1px,color:#0a0a0a
 style M1 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M2 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style M3 fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style W1 fill:#e4e4e7,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style W2 fill:#e4e4e7,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style W3 fill:#e4e4e7,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 style W4 fill:#e4e4e7,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
 

The totality of MK-677 evidence reveals a fundamental disconnect: the compound reliably manipulates the GH/IGF-1 axis, but manipulating that axis has not translated to the functional outcomes the enhancement community expects.

This is not unique to MK-677. Exogenous GH at pharmacological doses shows a similar pattern in clinical trials -- IGF-1 rises, but the "muscle-building" effect is modest at best and often statistically insignificant against placebo without concurrent anabolic androgenic compounds.

The GH/IGF-1 axis is one input into muscle protein synthesis among many. Elevating it in isolation does not override the dozens of other regulatory systems that control muscle growth.

What MK-677 does do reliably:

• Raise GH and IGF-1
• Improve deep sleep
• Reverse acute nitrogen wasting during caloric restriction
• Increase appetite
• Impair insulin sensitivity

What it does not do, based on the best available evidence:

• Build meaningful muscle
• Improve strength
• Reduce body fat
• Improve cognitive function directly
• Provide long-term body composition benefits that justify the metabolic cost

For Physique Enhancement

Caloric Deficit Use Case

The Murphy 1998 nitrogen retention data suggests potential anti-catabolic utility during aggressive cuts -- MK-677 reversed nitrogen wasting in a 7-day study of calorie-restricted subjects.^[1]

However, the intense appetite increase from ghrelin receptor activation may directly undermine the ability to maintain a caloric deficit. This creates a practical contradiction: the anti-catabolic benefit requires caloric restriction, but the appetite effect fights against caloric restriction.

Bulking Use Case

The rationale is limited. The fat-free mass gains observed in Nass 2008 -- approximately 1.5 kg over a year, not sustained into year two, with zero strength improvement -- are underwhelming compared to what most enhancement protocols achieve.^[2]

The appetite increase could theoretically assist hard gainers who struggle to eat enough, but the insulin resistance trade-off is significant. The cost-benefit calculation here is unfavorable for most individuals.

Sleep and Recovery Use Case

This may be the most defensible physique-related application. The 50% increase in deep sleep is not trivial.^[4]

Deep sleep is when GH-mediated tissue repair peaks, when memory consolidation occurs, and when systemic recovery from training is most active. For individuals whose recovery is bottlenecked by poor sleep quality, this is a measurable, clinically demonstrated benefit.

Stacking Considerations

Enhancement community reports include combinations with anabolic androgenic compounds, exogenous GH, and insulin.

Combining MK-677 with insulin is a particularly high-risk approach given MK-677's insulin-impairing properties. Water retention will mask physique assessment and confound scale-based tracking. Individuals already using compounds that stress metabolic function face compounded insulin resistance risk.

Internal links for related physique support: creatine (recovery, water retention context), zinc (hormonal optimization), hormonal optimization protocol.

For Cognitive Enhancement

The Sleep Pathway

The primary cognitive angle for MK-677 is indirect: better deep sleep supports memory consolidation, cognitive function, and mood regulation.

The Copinschi 1997 polysomnography data is the foundation here -- a 50% increase in slow-wave sleep is a meaningful improvement in the sleep phase most critical for cognitive restoration.^[4]

Enhancement community reports of "brain fog clearance" with MK-677 are likely attributable to improved sleep quality rather than any direct nootropic mechanism.

The Alzheimer's Data

The Sevigny 2008 trial provides direct evidence against a nootropic effect. MK-677 raised IGF-1 in Alzheimer's patients but produced zero cognitive improvement.^[13] IGF-1 has neuroprotective properties in animal models, but this has not translated to human cognitive benefit.

MK-677 is not a nootropic. It is a sleep-enhancing compound, and better sleep improves cognition. The distinction matters.

For individuals interested in targeted cognitive enhancement, see the nootropic focus protocol for compounds with direct cognitive evidence. For sleep-specific optimization, the sleep and recovery protocol covers magnesium, L-theanine, and complementary strategies.

Conclusions

MK-677 does exactly what it was designed to do: activate the ghrelin receptor, increase pulsatile GH release, and elevate IGF-1 to youthful levels. On that narrow measure, it works. The clinical data is clear and reproducible across multiple trials spanning decades.

The problem is that what the enhancement community expects to follow from higher IGF-1 -- meaningful muscle growth, improved body composition, greater strength -- has not materialized in any controlled trial.

The best available evidence, a 2-year RCT, found modest fat-free mass gains that did not persist, zero strength improvement, and significant metabolic cost in the form of insulin resistance.

The most defensible use case for MK-677 is sleep quality improvement, where the polysomnography data is strong and the benefit is meaningful. The anti-catabolic effect during caloric deficit has short-term support but is practically undermined by the appetite increase.

Body composition and strength goals are poorly served by this compound when assessed against the clinical evidence rather than internet anecdote.

Merck abandoned MK-677 after decades of investment because the risk-benefit ratio did not support regulatory approval. That decision was made with full access to all clinical data, including data that has never been published. It is a signal that should inform individual risk assessment.

References

1. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-325. PMID: 9467546
2. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485
3. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. PMID: 8954023
4. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-286. PMID: 9349662
5. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res. 2001;16(suppl 1):S284.
6. Svensson J, Lall S, Dickson SL, et al. Effects of growth hormone and its secretagogues on bone. Endocrine. 2001;14(1):63-66. PMID: 11322503
7. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621-645. PMID: 9331545
8. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470
9. Gauna C, Meyler FM, Janssen JA, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab. 2004;89(10):5035-5042. PMID: 15472199
10. Vestergaard ET, Djurhuus CB, Gjedsted J, et al. Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab. 2008;93(2):438-444. PMID: 18042651
11. Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004;52(4):516-523. PMID: 15066064
12. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400318
13. Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708. PMID: 18838748

Frequently Asked Questions